Ipsen


Prudent cost management in H1; FY20 goals reinstated

01/08/20 -"As expected, the consumer healthcare segment and the neurosciences franchisee were adversely impacted by the pandemic, though the oncology franchisee provided the much needed resilience. ..."

Pages
65
Language
English
Published on
01/08/20
You may also be interested by these reports :
10/08/20
Hikma’s H1 20 top-line acceleration was driven by COVID-19-related demand in Injectables and Generics and the economic recovery in Algeria propelled ...

10/08/20
Bayer (Buy, Germany) has managed to exhaust its shareholders and analysts alike as it navigated the stupidity of acquiring Monsanto back in 2017. As ...

07/08/20
After an impressive Q1, driven by COVID-19-induced stocking, growth fizzled out in Q2. GLP-1 offerings continue to do well, but headwinds in insulins ...

07/08/20
Despite the integration of BCN Pharma, Faes’ Q2 top-line came under pressure primarily due to the decline in sales of Bilastine (due to the reduction ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO